The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Is ASCT the right answer for all transplant eligible MM patients?
Francesca Gay
• 15 Sep 2019
Francesca Gay, MD, of University of Turin, Turin, Italy, debates whether ASCT is the right answer for all transplant eligible myeloma patients. Recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
